DailyDoctor Archive Specialties Get app
All nephrology briefings

The edition · Nephrology

Cochrane update: convective dialysis likely lowers death and cardiovascular death against haemodialysis

The third version of the review rates the mortality benefit at moderate certainty. Also: chronic hypoparathyroidism and heart attack risk, and a self-management trial in diabetes at risk of kidney disease.

The edition in brief

Today's nephrology edition closes on the updated Cochrane review of haemodiafiltration, haemofiltration and haemodialysis. Across 62 randomised trials and 6,897 adults with kidney failure, convective dialysis likely reduced all-cause death (RR 0.88, 0.80 to 0.96; 15 trials) and cardiovascular death (RR 0.78, 0.66 to 0.92; 9 trials), both with no heterogeneity and moderate certainty. Effects on non-fatal cardiovascular events, fatigue, access problems, hospital admission and quality of life were inconclusive. A meta-analysis of nine cohort studies with 134,598 people found chronic hypoparathyroidism associated with a higher hazard of myocardial infarction (HR 1.19, 1.06 to 1.35); associations with heart failure, arrhythmia, stroke and death were heterogeneous and lost significance on prediction intervals. A single-centre Chinese trial of 134 people with type 2 diabetes at high risk of kidney disease reported better HbA1c, eGFR, systolic pressure and LDL cholesterol after 12 weeks of structured self-management, but no change in albuminuria. The pearl covers how to read a falling eGFR after starting an SGLT2 inhibitor or RAAS blocker.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free